Skip to main content
Signal8
Launch Terminal

Silence Therapeutics plc (SLN)

Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Silence Therapeutics plc logo

Silence Therapeutics plc

NASDAQ:SLNHealthcare
-0.25%$19.75
AH$19.75+0.00%vs close
Mkt Cap$1.23B
Float5.47M
O/S62.2M
Vol
$ Vol
RVOL
Inst Own35.8%
SI53.5%
Earnings
Dilution
Silence Therapeutics plc logoNASDAQ:SLN$19.75-0.25%
Phase Distribution
8 lead-sponsored trials·1 active·6 completed
Early Phase 11
Phase 14
Phase 1/22
Phase 21
Status Overview
Active, not recruiting1
Completed6
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Completed

    Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

    SLN360, Placebo

    Cardiovascular Diseases, Atherosclerosis +1

    Enrollment
    180
    Start
    Dec 2022
    Primary Completion
    Jan 2024
    Completion
    Jul 2024
    NCT05537571
  • Phase 1/2
    Completed

    Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)

    Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1

    Carcinoma, Pancreatic Ductal

    Enrollment
    29
    Start
    Mar 2013
    Primary Completion
    Aug 2015
    Completion
    Jan 2016
    NCT01808638
  • Phase 1/2
    Active, not recruiting

    Study to Assess SLN124 in Patients With Polycythemia Vera

    SLN124, Placebo

    Polycythemia Vera

    Enrollment
    69
    Start
    Jan 2023
    Primary Completion
    Sep 2026est.
    Completion
    Mar 2030est.
    NCT05499013
  • Phase 1
    Completed

    Study With Atu027 in Patients With Advanced Solid Cancer

    Atu027

    Advanced Solid Tumors

    Enrollment
    34
    Start
    Jun 2009
    Primary Completion
    Jul 2012
    Completion
    Sep 2012
    NCT00938574
  • Phase 1
    Withdrawn

    Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124

    SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo

    Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome

    Enrollment
    0
    Start
    Aug 2019
    Primary Completion
    Sep 2021est.
    Completion
    Oct 2021est.
    NCT04176653
  • Phase 1
    Completed

    Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

    SLN360, Placebo

    Hyperlipidemias, Dyslipidemias +1

    Enrollment
    70
    Start
    Nov 2020
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT04606602
  • Phase 1
    Completed

    A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

    SLN124, Placebo

    Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome +1

    Enrollment
    44
    Start
    Apr 2021
    Primary Completion
    May 2023
    Completion
    May 2023
    NCT04718844
  • Early Phase 1
    Completed

    A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers

    SLN124, Placebo

    Healthy Volunteers

    Enrollment
    24
    Start
    Sep 2020
    Primary Completion
    Mar 2021
    Completion
    Mar 2021
    NCT04559971
Search ClinicalTrials.gov for “Silence Therapeutics”